Clinical Trial: Alzheimer's Disease THErapy With NEuroaid II

U.S., Sept. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07191028) titled 'Alzheimer's Disease THErapy With NEuroaid II' on Sept. 02.

Brief Summary: ATHENE II is a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial designed to evaluate the efficacy and safety of MLC901 in subjects with mild to moderate Alzheimer's disease, as well as its effects on plasma biomarkers compared to placebo.

Study Start Date: Dec., 2025

Study Type: INTERVENTIONAL

Condition: Alzheimer's Disease Dementia

Intervention: DRUG: MLC 901

Oral capsule, 2 capsules 3 times a day for 12 months

DRUG: Placebo

Oral capsule, 2 capsules 3 times a day for 12 months

Recruitment Status: NOT_YET_RECRUITING

S...